SCHEMBL22027030

SCHEMBL22027030

COc1ccc(C23CCC(C(=O)O)(CC2)C3)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAAA Q02083 1/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ TET3 O43151 1/20 0.44
▸ FBXL19 Q6PCT2 1/20 0.44
▸ CXXC5 Q7LFL8 1/20 0.44
▸ TET1 Q8NFU7 1/20 0.44
▸ KDM2B Q8NHM5 1/20 0.44
▸ CXXC4 Q9H2H0 1/20 0.44
▸ KDM2A Q9Y2K7 1/20 0.44
▸ LMNA P02545 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HSD11B1 P28845 2/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ OPRM1 P35372 2/20 0.41
▸ OPRL1 P41146 2/20 0.41
▸ ATM Q13315 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22027200 0.94 KMT2A (0.45) NAAAKMT2ATET3FBXL19CXXC5
SCHEMBL22027277 0.90 DGAT1 (0.46) NAAAKMT2ATET3FBXL19CXXC5
SCHEMBL21544698 0.88 NAAA (0.50) NAAAKMT2ATET3FBXL19CXXC5
SCHEMBL22026919 0.86 NAAA (0.46) NAAALMNASMN1; SMN2HSD11B1CA1
SCHEMBL22027090 0.83 NAAA (0.47) NAAAKMT2ALMNASMN1; SMN2HSD11B1
SCHEMBL22026882 0.81 LMNA (0.45) NAAAKMT2ALMNASMN1; SMN2HSD11B1
SCHEMBL21805979 0.79 ATM (0.44) NAAAKMT2ALMNASMN1; SMN2CA1
SCHEMBL22026922 0.79 SMN1; SMN2 (0.46) NAAAKMT2ALMNASMN1; SMN2HSD11B1
SCHEMBL12936217 0.78 KMT2A (0.66) KMT2ALMNASMN1; SMN2HSD11B1
SCHEMBL25387067 0.77 NAAA (0.52) NAAALMNASMN1; SMN2HSD11B1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220002309-A1 SSAO INHIBITORS AND USES THEREOF METACRINE, INC. 2022-01-06 — — US disclosed
US-20220002309-A1 SSAO INHIBITORS AND USES THEREOF METACRINE, INC. 2022-01-06 — — US disclosed
US-20200181104-A1 SSAO INHIBITORS AND USES THEREOF METACRINE, INC. 2020-06-11 — — US disclosed
US-20200181104-A1 SSAO INHIBITORS AND USES THEREOF METACRINE, INC. 2020-06-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002309-A1 SSAO INHIBITORS AND USES THEREOF AOX1, AOC2, MAOA NAAA 720/4885KMT2A 3212/4885TET3 1573/4885
US-20200181104-A1 SSAO INHIBITORS AND USES THEREOF AOX1, AOC2, MAOA NAAA 720/4885KMT2A 3212/4885TET3 1573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback